Seres Therapeutics, Inc. (MCRB)
After hours: 04:25PM EST
- Business Wire
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., November 24, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website.
- Motley Fool
Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday
The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with Nestlé Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).
- Zacks
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
